Declining treatment-related and overall mortality in children with newly diagnosed advanced-stage non‑Hodgkin lymphoma treated in a paediatric cancer centre during 2013‑2024, Shanghai, China
The 3-year overall mortality and TRM cumulative incidence were 11.20% ± 1.44% and 2.11% ± 0.65% respectively.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.
- Overcoming PD‑1 Resistance in Relapsed/Refractory Hodgkin Lymphoma
- Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
- Late cardiopulmonary morbidity in patients with Hodgkin lymphoma: a retrospective nationwide registry study
- Combination of Acimtamig and AlloNK Effective in R/R Classical Hodgkin Lymphoma